|
Demographic data
|
Group
|
P value
|
|---|
|
Control (n = 27)
|
Intervention (n = 25)
|
|---|
|
Age (mean ± SD)
|
45.0 ± 8.36
|
41.0 ± 8.61
|
0.099
|
|
Weight (mean ± SD)
|
68.0 ± 9.52
|
70.0 ± 9.71
|
0.45
|
|
BMI (mean ± SD)
|
27.4 ± 4.37
|
27.7 ± 4.03
|
0.78
|
|
BSA (mean ± SD)
|
1.7 ± 0.1
|
1.7 ± 0.13
|
0.35
|
|
Positive family history n (%)
|
8 (29.6)
|
6 (24.0)
|
0.65
|
|
Regular Menstruation n (%)
|
20 (74.1)
|
21 (84.0)
|
0.38
|
|
Married n (%)
|
26 (96.0)
|
22 (88.0)
|
0.34
|
|
Parity (mean±SD)
|
2.8 ± 1.96
|
1.88 ± 1.36
|
0.069
|
|
Primary tumor size mm (mean±SD)
|
31.3 ± 19.54
|
41.2 ± 32.78
|
0.364
|
|
Initial T-stage n (%)
|
|
TI
|
7 (25.9)
|
4 (16.0)
|
0.611
|
|
T2
|
6 (22.2)
|
9 (36.0)
|
|
T3
|
4 (14.8)
|
5 (20.0)
|
|
T4
|
10 (37.0)
|
7 (28.0)
|
|
Tumor grade n (%)
|
|
I
|
6 (22.2)
|
3 (12.0)
|
0.657
|
|
II
|
13 (48.1)
|
13 (52.0)
|
|
III
|
8 (29.6)
|
9 (36.0)
|
|
Node involvement n (%)
|
21 (77.7)
|
22 (88.0)
|
0.469
|
|
Hormonal status
|
|
ER+ n (%)
|
21 (85.0)
|
23 (84.0)
|
1.00
|
|
Extent of positivity (mean±SD)
|
74.3 ± 25.1
|
59.9 ± 33.9
|
0.104
|
|
PR+ n (%)
|
19 (70.0)
|
14 (56.0)
|
0.28
|
|
Extent of positivity (mean±SD)
|
48.7 ± 32.7
|
46.78 ± 32.7
|
0.869
|
|
HER2+ n (%)
|
10 (37.0)
|
8 (32.0)
|
0.43
|
|
ki67+a n (%)
|
15 (55.5)
|
19 (76.0)
|
0.122
|
|
ki67 (mean±SD)
|
34.8 ± 27.8
|
37.2 ± 23.7
|
0.742
|
|
Molecular Subtype
|
|
HR+/HER2-
|
12 (44.4%)
|
9 (36%)
|
0.98
|
|
HR+/HER2+
|
11 (40.1%)
|
12 (48%)
|
|
HR-/HER2+
|
2 (7.4%)
|
2 (8%)
|
|
TNBC
|
2 (7.4%)
|
2 (8%)
|
|
TILb n (%)
|
|
+
|
13 (48.1)
|
10 (40.0)
|
0.554
|
|
-
|
14 (51.9)
|
15 (60.0)
|
- BMI Body mass index, BSA Body surface area, ER Estrogen receptor, PR Progesterone receptor, NACT neoadjuvant chemotherapy, TNBC Triple negative breast cancer, TIL Tumor-infiltrating lymphocytes
- aCut-off for ki67 positivity was 20%
- bCut-off for TIL was 10%
